These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 31570691)

  • 1. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
    Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
    Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p.
    Tian Y; Li L; Lin G; Wang Y; Wang L; Zhao Q; Hu Y; Yong H; Wan Y; Zhang Y
    Leuk Lymphoma; 2021 Jul; 62(7):1574-1584. PubMed ID: 33682607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis.
    Yuan J; Yang J; Wang R; Hao H; Li J
    Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):429-436. PubMed ID: 35352617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long Non-Coding RNA Paternally Expressed Imprinted Gene 10 (PEG10) Elevates Diffuse Large B-Cell Lymphoma Progression by Regulating Kinesin Family Member 2A (KIF2A) via Targeting MiR-101-3p.
    Zhao J; Su L; Jiang J
    Med Sci Monit; 2020 Sep; 26():e922810. PubMed ID: 32976381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Role and Mechanism of ZEB1 in Regulating Cervical Carcinoma Progression via Modulating PD-1/PD-L1 Checkpoint.
    Lin Y; Wang X
    Comput Math Methods Med; 2022; 2022():1565094. PubMed ID: 35535226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. lncRNA TUG1-Mediated Mir-142-3p Downregulation Contributes to Metastasis and the Epithelial-to-Mesenchymal Transition of Hepatocellular Carcinoma by Targeting ZEB1.
    He C; Liu Z; Jin L; Zhang F; Peng X; Xiao Y; Wang X; Lyu Q; Cai X
    Cell Physiol Biochem; 2018; 48(5):1928-1941. PubMed ID: 30092578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.
    Song S; Yu W; Lin S; Zhang M; Wang T; Guo S; Wang H
    Cancer Biol Ther; 2018 Jul; 19(7):573-583. PubMed ID: 29667486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
    Sun JR; Zhang X; Zhang Y
    Cell Mol Biol Lett; 2019; 24():68. PubMed ID: 31844419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA PCAT-1 promotes the progression of osteosarcoma via miR-508-3p/ZEB1 axis.
    Chang L; Jia DL; Cao CS; Wei H; Li ZQ
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2517-2527. PubMed ID: 33829438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking SNHG14 Antagonizes Lipopolysaccharides-Induced Acute Lung Injury via SNHG14/miR-124-3p Axis.
    Zhu Y; Wang Y; Xing S; Xiong J
    J Surg Res; 2021 Jul; 263():140-150. PubMed ID: 33652176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA TTN-AS1 drives invasion and migration of lung adenocarcinoma cells via modulation of miR-4677-3p/ZEB1 axis.
    Zhong Y; Wang J; Lv W; Xu J; Mei S; Shan A
    J Cell Biochem; 2019 Oct; 120(10):17131-17141. PubMed ID: 31173403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA SNHG14 promotes osteosarcoma progression via miR-433-3p/FBXO22 axis.
    Hou XK; Mao JS
    Biochem Biophys Res Commun; 2020 Mar; 523(3):766-772. PubMed ID: 31948764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of long non-coding RNA MALAT1 elevates microRNA-429 to suppress the progression of hypopharyngeal squamous cell carcinoma by reducing ZEB1.
    Liu X; Zhao W; Wang X
    Life Sci; 2020 Dec; 262():118480. PubMed ID: 32980391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA PCAT1 enhances cell proliferation, migration and invasion by miR-508-3p/NFIB axis in diffuse large B-cell lymphoma.
    Tian M; Li Y; Zheng W; Liu QQ; Zhang XL; Liu JL; Zhang S; Sheng YX; Fan CB; Zhang WL
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2567-2576. PubMed ID: 33829443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 18. Silenced lncRNA SNHG14 restrains the biological behaviors of bladder cancer cells via regulating microRNA-211-3p/ESM1 axis.
    Feng R; Li Z; Wang X; Ge G; Jia Y; Wu D; Ji Y; Wang C
    Cancer Cell Int; 2021 Jan; 21(1):67. PubMed ID: 33482820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-Coated si-SNHG14 Regulated PD-L1 Expression and Decreased Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells.
    Yu H; Zhang C; Li W; Sun X; Liu Q; Wang D
    J Biomed Nanotechnol; 2021 Oct; 17(10):1993-2002. PubMed ID: 34706799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA SNHG14 promotes malignancy of prostate cancer by regulating with miR-5590-3p/YY1 axis.
    Luo ZF; Peng Y; Liu FH; Ma JS; Hu G; Lai SL; Lin H; Chen JJ; Zou GM; Yan Q; Sui WG
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4697-4709. PubMed ID: 32432733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.